Imigran (Sumatriptan)

Sumatriptan selectively stimulates serotonin 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve fibers. This action produces vasoconstriction of dilated intracranial vessels and blocks the release of inflammatory neuropeptides, thereby reducing migraine pain and related neurological disturbances.

The prescribed dose of Imigran is determined by a qualified healthcare professional based on the individual’s clinical condition. In practice, the product is supplied as a 6 mg/0.5 mL solution for subcutaneous injection, and the prescriber decides the exact dosing schedule and frequency.

Safety data for sumatriptan in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss the risks and alternatives with their healthcare provider.

To order Imigran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if required), and any necessary import documentation.

Imigran (sumatriptan) belongs to the Triptan class, which provides rapid, targeted relief by acting on serotonin receptors. Compared with non‑specific analgesics such as NSAIDs, Triptans address the underlying vascular and neurogenic mechanisms of migraine, often achieving faster pain resolution. Other Triptans (e.g., rizatriptan, zolmitriptan) have similar efficacy but differ in formulation and onset speed.

Imigran should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not freeze the product. Keep the vial tightly sealed until use and discard any solution that appears discolored or contains particles.

Imigran is supplied as a sterile solution for subcutaneous injection. The recommended administration technique involves cleaning the injection site, typically the outer thigh or abdomen, and delivering the 0.5 mL dose using a suitable needle. Patients should be instructed by a healthcare professional on proper injection technique and disposal of sharps.

Serious risks include chest pain or tightness that may signal coronary vasospasm, severe hypertension, and allergic reactions ranging from rash to anaphylaxis. Rarely, sumatriptan can precipitate serotonin syndrome, especially when combined with other serotonergic agents. Immediate medical attention is required if any of these symptoms occur.

Imigran is contraindicated in patients with a known hypersensitivity to sumatriptan or any component of the formulation, uncontrolled hypertension, recent myocardial infarction or stroke, peripheral vascular disease, and in individuals currently taking other Triptans, ergot derivatives, or monoamine oxidase inhibitors. Clinicians should also avoid prescribing it to patients with severe hepatic or renal impairment without careful assessment.